CoreMedic’s ChordArt TMVr System Marks First Successful Application in FIH Study

November 20, 2023—CoreMedic GmbH, a Germany-based cardiology company focused on treatment of mitral valve regurgitation, recently announced the first successful application of the company’s ChordArt technology for transcatheter mitral valve repair (TMVr).

The company reported that the patient was treated as part of CoreMedic’s first-in-human (FIH) trial for percutaneous mitral chordae tendineae replacement with the ChordArt TMVr system. The patient had severe degenerative mitral regurgitation caused by mitral leaflet flail.

According to CoreMedic, the ChordArt device is being developed as catheter-based first line treatment option for primary mitral regurgitation. The device is designed to repair the mitral valve by replacing damaged mitral valve chords with a physiological approach respecting the natural anatomy. With a minimal footprint, the implant allows for possible future therapy needs.

Professor Alberto Weber, MD, who is Founder and Chief Medical Officer of CoreMedic, commented in the company’s press release, “Percutaneous, transseptal mitral valve repair of flail leaflets is now a reality. A safe and reproducible solution that invites an end to watchful waiting in patients with severe degenerative mitral regurgitation.”

Prof. Weber continued, “My special thanks to the professionals who made this patient happy: Professor Maurizio Taramasso, MD, Professor Michel Zuber, MD, and Leonora Zuberi from our Swiss team as well as Professor Kęstutis Ručinskas, MD, Dr. Diana Zakarkaitė, Dr. Andrej Podkopajev, Dr. Vilnius Janušauskas, and Professor Giedrius Davidavičius, MD, at the Vilnius University Hospital Santaros Klinikos in Vilnius Lithuania.”

Thomas Bauer, Chief Technology Officer and Cofounder of CoreMedic, added, “We are very happy for the patient and are delighted about the technical success as well. Results from the 5-year follow-up of our initial surgical study with the ChordArt system have been exceptionally promising. Now we have demonstrated the ability to percutaneously deliver this implant less invasively, via the transfemoral, transseptal route—an outstanding achievement, which the whole cross-functional team is extremely proud of.”

Also in the press release, CoreMedic’s CEO Josef Bogenschütz stated, “We are thrilled to achieve this historic milestone with our revolutionary ChordArt TMVr system, a novel approach for percutaneous mitral valve repair. Thank you to all who played a crucial role in making this success true. This achievement is a testament to the dedication and hard work of our exceptional team, and we are deeply appreciative of their contributions. Our cutting-edge solution enables us to position ourselves as leaders in the field of catheter based mitral valve repair. We are committed to redefining the gold standard, thereby setting new benchmarks for excellence in the future.”